Global pharma major Pfizer is sending its medicines worth $70 million (over ₹510 crores), from its distribution centres in the U.S., Europe and Asia, that have been identified as part of India’s Covid-19 treatment protocol, the company’s Chairman and CEO Albert Bourla said on May 3.
“We are deeply concerned by the critical COVID-19 situation in India, and our hearts go out to you, your loved ones and all the people of India," says Pfizer Chairman and CEO Albert Bourla.
